Results 1 to 10 of about 6,746 (106)
Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2
Cells, 2022 B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that mediates the escape of tumor cells from immunosurveillance. Consequently, BTLA and its ligand herpesvirus entry mediator (HVEM) are potentially immunotherapeutic targets. However,
Shan Gao, Yibo Xi, Tian-Tian Zhang
exaly +3 more sources
Role of BTLA in ovarian cancer and its clinical prognostic significance based on multi-omics analysis [PDF]
Journal of Ovarian ResearchBackground Ovarian cancer (OV) is a highly lethal gynecological malignancy with limited effective biomarkers for prognosis and precision immunotherapy.
Yiliminuer Abulajiang, Yumei Wu
doaj +2 more sources
Roles of BTLA in Immunity and Immune Disorders
Frontiers in Immunology, 2021 B and T lymphocyte attenuator (BTLA) is one of the most important cosignaling molecules. It belongs to the CD28 superfamily and is similar to programmed cell death-1 (PD-1) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) in terms of its ...
Chunxia Li
exaly +3 more sources
Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
Frontiers in Molecular Biosciences, 2020 BackgroundB and T lymphocyte attenuator (BTLA) is a co-signaling protein belonging to the CD28 immunoglobulin superfamily. However, the role of BTLA in prognosis and immunotherapy of colorectal cancer (CRC) remains unclear.MethodsWe evaluated the ...
Jingjing Song
exaly +3 more sources
Cells, 2021 In our previous study, while chronic lymphocytic leukemia (CLL) cases showed higher levels of B and T lymphocyte attenuator (BTLA) mRNA compared to controls, lower BTLA protein expression was observed in cases compared to controls.
Jacek Rolinski +2 more
exaly +3 more sources
BTLA Inhibition Has a Dominant Role in the Cis-Complex of BTLA and HVEM
Frontiers in Immunology, 2022 The engagement of the herpesvirus entry mediator (HVEM, TNFRSF14) by the B and T lymphocyte attenuator (BTLA) represents a unique interaction between an activating receptor of the TNFR-superfamily and an inhibitory receptor of the Ig-superfamily.
Peter Steinberger +2 more
exaly +3 more sources
Frontiers in Immunology, 2021 B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor that is expressed by lymphoid cells and regulates the immune response. Consistent with an inhibitory role for BTLA, the disease is exacerbated in BTLA-deficient lupus mice.
Matthieu Sawaf +2 more
exaly +3 more sources
BTLA Expression and Function Are Impaired on SLE B Cells
Frontiers in Immunology, 2021 B- and T-lymphocyte attenuator (BTLA/CD272) is an inhibitory checkpoint molecule expressed on T and B cells. Prior studies reported defective function of BTLA by T cells in patients with systemic lupus erythematosus (SLE), whereas nothing is known about ...
Hector Rincón-Arévalo +2 more
exaly +3 more sources
BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy [PDF]
PharmaceuticalsB and T lymphocyte attenuator (BTLA) is a unique co-inhibitory receptor of the CD28 immunoglobulin superfamily that exhibits dual regulatory functions in immune activation and tolerance.
Ming-Cheng Chang +3 more
doaj +2 more sources
Admission CD4+ T cell BTLA expression and its association with infection risk and respiratory outcomes in sepsis [PDF]
Frontiers in Cellular and Infection MicrobiologyObjectiveT cell co-inhibitory molecule upregulation is linked to sepsis-induced immune suppression, but the relationship between B and T lymphocyte attenuator (BTLA) expression and ICU-acquired infection or organ function recovery in sepsis remains ...
Shuwei Ning +6 more
doaj +2 more sources